ml-3000 has been researched along with Disease Models, Animal in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (40.00) | 29.6817 |
2010's | 7 (46.67) | 24.3611 |
2020's | 2 (13.33) | 2.80 |
Authors | Studies |
---|---|
Bandresh, R; Shrivastava, SK; Srivastava, P; Tripathi, A; Tripathi, PN | 1 |
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
Balansky, R; De Flora, S; Izzotti, A; La Maestra, S; Micale, RT; Pulliero, A | 1 |
Dehpour, AR; Fakhraei, N; Ghasemkhani, N; Mokhtari, R; Mousavi, SE; Saberi, P | 1 |
Lu, R; Lv, P; Su, W; Zhang, K; Zhao, J | 1 |
Brewer, M; Cruz-Monserrate, Z; Houchen, CW; Janakiram, NB; Kumar, G; Lightfoot, S; Madka, V; May, R; Mohammed, A; Patlolla, JM; Rao, CV; Ritchie, RL; Sadeghi, M; Steele, VE; Yamada, HY | 1 |
Kalonia, H; Kumar, A; Kumar, P | 1 |
Lee, J; Sharma, S; Steele, VE; Zhou, J | 1 |
Dulin, JN; Grill, RJ; Moore, ML | 1 |
Boileau, C; Jouzeau, JY; Laufer, S; Martel-Pelletier, J; Moldovan, F; Netter, P; Pelletier, JP; Tries, S | 1 |
Evans, R | 1 |
Boileau, C; Brunet, J; Laufer, S; Martel-Pelletier, J; Moreau, M; Pelletier, JP | 1 |
Cerletti, C; Dell'Elba, G; Evangelista, V; Manarini, S; Rotondo, S | 1 |
Egido, J; Gómez-Gerique, JA; Gómez-Hernández, A; González, A; Ortega, L; Sánchez-Galán, E; Tuñón, J; Vidal, C | 1 |
Gay, RE; Gay, S; Laufer, S; Neidhart, M; Pataky, F; Tries, S | 1 |
15 other study(ies) available for ml-3000 and Disease Models, Animal
Article | Year |
---|---|
Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Carrageenan; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Edema; Female; Indolizines; Lipoxygenase; Lipoxygenase Inhibitors; Male; Mice; Molecular Structure; Prostaglandin-Endoperoxide Synthases; Rats; Structure-Activity Relationship; Ulcer | 2017 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Modulation of smoke-induced DNA and microRNA alterations in mouse lung by licofelone, a triple COX-1, COX-2 and 5-LOX inhibitor.
Topics: Animals; Anticarcinogenic Agents; Arachidonate 5-Lipoxygenase; Carcinogenesis; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; DNA Adducts; DNA Damage; Drug Administration Schedule; Female; Humans; Inflammation; Lung; Lung Neoplasms; Male; Membrane Proteins; Mice; MicroRNAs; Pyrroles; Time Factors; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2020 |
Licofelone Attenuates LPS-induced Depressive-like Behavior in Mice: A Possible Role for Nitric Oxide.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Injections, Intraperitoneal; Lipopolysaccharides; Male; Mice; Nitric Oxide; Pyrroles | 2018 |
Immunomodulatory effectiveness of licofelone in preventing epidural fibrosis in post-laminectomy rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cicatrix; Disease Models, Animal; Double-Blind Method; Epidural Space; Failed Back Surgery Syndrome; Fibrosis; Gene Expression; Hydroxyproline; Interleukin-6; Laminectomy; Lumbar Vertebrae; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; RNA, Messenger; Tissue Adhesions; Transforming Growth Factor beta1 | 2015 |
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arachidonic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Proliferation; Ceruletide; Cyclooxygenase 2; Disease Models, Animal; Disease Progression; Doublecortin-Like Kinases; Lipoxygenase Inhibitors; Mice; Mice, Knockout; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatitis; Protein Serine-Threonine Kinases; Pyrroles | 2015 |
Licofelone attenuates quinolinic acid induced Huntington like symptoms: possible behavioral, biochemical and cellular alterations.
Topics: Animals; Behavior, Animal; Biochemical Phenomena; Corpus Striatum; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Huntington Disease; Lipid Peroxidation; Lipoxygenase Inhibitors; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Oxidative Stress; Pyrroles; Quinolinic Acid; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2011 |
Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Biological Assay; Biomarkers, Tumor; Disease Models, Animal; Disease Progression; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Models, Chemical; Pyrroles | 2011 |
The dual cyclooxygenase/5-lipoxygenase inhibitor licofelone attenuates p-glycoprotein-mediated drug resistance in the injured spinal cord.
Topics: Animals; Arachidonate 5-Lipoxygenase; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Disease Models, Animal; Drug Resistance; Enzyme Inhibitors; Gene Knockout Techniques; Male; Mice; Mice, Knockout; Neuroprotective Agents; Prostaglandin-Endoperoxide Synthases; Pyrroles; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Recovery of Function; Riluzole; Spinal Cord Injuries; Tissue Array Analysis | 2013 |
Licofelone (ML-3000), a dual inhibitor of 5-lipoxygenase and cyclooxygenase, reduces the level of cartilage chondrocyte death in vivo in experimental dog osteoarthritis: inhibition of pro-apoptotic factors.
Topics: Acetates; Administration, Oral; Animals; Apoptosis; Cartilage, Articular; Chondrocytes; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Immunohistochemistry; Interleukin-1; Matrix Metalloproteinase 1; Nitric Oxide Synthase; Osteoarthritis; Probability; Pyrroles; Reference Values; Sensitivity and Specificity; Statistics, Nonparametric | 2002 |
Anti arthritic drugs--SMi conference: dual inhibitors. 28-29 April 2003, London, UK.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Clinical Trials as Topic; Complement Activation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Models, Animal; Humans; Isoenzymes; Lipoxygenase Inhibitors; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrroles; Thalidomide; Tumor Necrosis Factor-alpha | 2003 |
Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity.
Topics: Acetates; Animals; Anterior Cruciate Ligament; Cartilage, Articular; Collagenases; Disease Models, Animal; Disease Progression; Dogs; Enzyme Inhibitors; Metalloproteases; Osteoarthritis, Knee; Pyrroles; Stifle | 2006 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Electrocardiography; Heart Rate; Inflammation; Lactones; Leukotriene B4; Lipoxygenase Inhibitors; Male; Myocardial Ischemia; N-Formylmethionine Leucyl-Phenylalanine; Pyrroles; Rabbits; Sulfones; Thromboxane A2; Time Factors | 2006 |
Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
Topics: Acetates; Animals; Atherosclerosis; Chemokine CCL2; Cyclooxygenase Inhibitors; Dinoprostone; Disease Models, Animal; Leukotriene B4; Lipids; Lipoxygenase Inhibitors; Macrophages; Male; NF-kappa B; Pyrroles; Rabbits; RNA, Messenger; Thromboxane B2; Tunica Intima | 2007 |
Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
Topics: Acetates; Animals; Arachidonate 5-Lipoxygenase; Arthritis, Experimental; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Lipoxygenase Inhibitors; Probability; Prostaglandin-Endoperoxide Synthases; Pyrroles; Range of Motion, Articular; Rats; Rats, Inbred Lew; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2001 |